

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**203388Orig1s000**

**MICROBIOLOGY REVIEW(S)**

# Product Quality Microbiology Review

21 December 2011

**NDA:** 203388/N-000

**Drug Product Name**

**Proprietary:**

N/A.

**Non-proprietary:**

USAN Vismodegib.

**Review Number:**

1.

## **Dates of Submission(s) Covered by this Review**

<b>Submit</b>	<b>Received</b>	<b>Review Request</b>	<b>Assigned to Reviewer</b>
08 SEP 2011	08 SEP 2011	14 SEP 2011	15 JUN 2011
17 OCT 2011	18 OCT 2011	N/A	N/A

**Applicant/Sponsor**

**Name:**

Genentech, Inc.

**Address:**

1 DNA Way MS#241B  
South San Francisco, CA  
94080-4990

**Representative:**

Wen Liu, Ph.D.

**Telephone:**

650-467-1535

**Name of Reviewer:**

John W. Metcalfe, Ph.D.

**Conclusion:**

Recommend approval.

---

## Product Quality Microbiology Data Sheet

- A. 1. **TYPE OF SUBMISSION:** 505(b)(1) New Drug Application.
2. **SUBMISSION PROVIDES FOR:** Marketing authorization.
3. **MANUFACTURING SITE:**  
 (b) (4)
4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**
- Hard capsule.
  - Oral administration.
  - 150 mg.
5. **METHOD(S) OF STERILIZATION:** The subject drug product is non-sterile.
6. **PHARMACOLOGICAL CATEGORY:** The subject drug product is indicated for the treatment of advanced basal cell carcinoma.
- B. **SUPPORTING/RELATED DOCUMENTS:** None.

C. **REMARKS:**

The subject application is submitted electronically in CTD format.

The following Microbiology Information Request was forwarded to the applicant in the 74 Day Letter:

*It is understood that the microbial limits tests will be performed according to USP<61> and <62>. Provide the test methods for microbial limits testing along with data sets verifying the suitability of use of the stated microbial limits tests with the subject drug product.*

The applicant provided a response to this IR on 17 October 2011. The responses are summarized and evaluated in appropriate sections of this review.

**File Name:** N203388N000R1.doc

---

---

**Executive Summary**

**I. Recommendations**

- A. **Recommendation on Approvability** – NDA 203388 is recommended for approval on the basis of issues pertaining to product quality microbiology.
- B. **Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – Not applicable.

**II. Summary of Microbiology Assessments**

- A. **Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** -  (b) (4)
- B. **Brief Description of Microbiology Deficiencies** – There are no microbiology deficiencies identified.
- C. **Assessment of Risk Due to Microbiology Deficiencies** – Not applicable.

**III. Administrative**

- A. **Reviewer's Signature** \_\_\_\_\_  
John W. Metcalfe, Ph.D.
- B. **Endorsement Block** \_\_\_\_\_  
Bryan S. Riley, Ph.D.
- C. **CC Block**  
N/A

5 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOHN W METCALFE  
12/21/2011

BRYAN S RILEY  
12/21/2011  
I concur.

## PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

**NDA Number:** 203388

**Applicant:** Genentech, Inc.

**Letter Date:** 08 September 2011

**Drug Name:** Vismodegib

**NDA Type:** 505(b)(1)

**Stamp Date:** 08 September 2011

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		Module 3.2.P.
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		Module 3.2.P.3.3.
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?		X	N/A. Product is non-sterile.
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?		X	N/A. Product is a capsule and is non-sterile.
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		Table P.5.1-1.
7	Has the applicant submitted the results of analytical method verification studies?		X	This will be requested but is not a reason for RTF.
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?			N/A.
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments:

The following comment should be forwarded to the applicant in the 74 Day Letter:

*It is understood that the microbial limits tests will be performed according to USP<61> and <62>. Provide the test methods for microbial limits testing along with data sets verifying the suitability of use of the stated microbial limits tests with the subject drug product.*

\_\_\_\_\_  
John W. Metcalfe, Ph.D.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Bryan S. Riley, Ph.D.

\_\_\_\_\_  
Date

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOHN W METCALFE

09/30/2011

The application is filable from a product quality microbiology perspective.

BRYAN S RILEY

09/30/2011

I concur.